Financial Performance - The company's operating revenue for Q1 2022 was CNY 1,817,858,958.69, representing a 101.55% increase compared to CNY 901,947,880.46 in the same period last year[4]. - Net profit attributable to shareholders for Q1 2022 was CNY 518,416,798.73, a 13.82% increase from CNY 455,480,291.91 year-on-year[4]. - The net profit from operating activities for Q1 2022 was CNY 378,410,426.28, showing a significant increase of 65.31% compared to CNY 228,909,261.61 in the previous year[4]. - Basic and diluted earnings per share for Q1 2022 were both CNY 0.60, reflecting a 15.38% increase from CNY 0.52 in the previous year[4]. - The net profit for the period was ¥656,002,308.83, down from ¥757,164,023.00 in the previous period, reflecting a decrease of approximately 13.3%[24]. - The net profit attributable to the parent company was approximately 573.97 million, compared to 722.55 million in the previous period, reflecting a decrease of about 20.5%[25]. - The total comprehensive income attributable to the parent company was approximately 517.87 million, up from 457.76 million in the previous period, indicating an increase of about 13.1%[26]. Cash Flow - The net cash flow from operating activities for Q1 2022 was CNY 303,078,662.63, which is a 27.16% increase from CNY 238,339,757.83 in the same period last year[4]. - Cash inflow from operating activities was approximately 1.84 billion, compared to 1.04 billion in the previous period, showing an increase of about 76%[63]. - Cash outflow from investing activities totaled approximately 1.53 billion, resulting in a net cash flow from investing activities of approximately -1.29 billion[69]. - Cash inflow from financing activities was approximately 1.01 billion, while cash outflow totaled approximately 479.01 million, leading to a net cash flow from financing activities of approximately 533.08 million, compared to 82.96 million in the previous period[69]. Assets and Liabilities - Total assets at the end of Q1 2022 were CNY 24,803,252,427.71, a 4.47% increase from CNY 23,741,171,551.32 at the end of the previous year[4]. - The company’s total liabilities increased to ¥3,629,856,135.03 from ¥3,135,974,351.68, reflecting a rise of approximately 15.8%[21]. - Long-term equity investments increased by 64.62% to CNY 1,216,247,844.57 due to increased investments in joint ventures during the reporting period[7]. - Inventory at the end of the period was ¥7,642,168.46, up from ¥6,095,078.95 at the beginning of the year, indicating an increase of approximately 25.4%[18]. Operating Costs and Expenses - Operating costs rose by 132.28% to ¥1,112,011,414.78 from ¥478,741,538.49, mainly due to increased costs associated with COVID-19 vaccine clinical trials[8]. - Management expenses increased by 39.22% to ¥158,946,738.06 from ¥114,168,850.78, attributed to a rise in the number and compensation of management personnel[8]. - The company reported a significant increase in tax expenses by 137.02% to ¥82,031,810.24 from ¥34,609,998.43, driven by profit growth[8]. - Research and development expenses for the period were ¥56,987,790.58, compared to ¥46,970,780.14 in the previous period, an increase of about 21.5%[23]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 49,909[9]. - The largest shareholder, Ye Xiaoping, holds 20.32% of shares, totaling 177,239,541 shares[10]. - The company repurchased shares, resulting in treasury stock increasing by 44.05% to CNY 817,568,540.51[7]. Other Income and Gains - Other income increased by 175.62% to ¥7,197,266.19 from ¥2,611,291.27, mainly due to increased government subsidies received[8]. - Investment income grew by 71.63% to ¥55,553,335.98 from ¥32,367,209.75, resulting from gains from the disposal of long-term assets[8]. - Non-operating income from government subsidies amounted to ¥3,047,160.06 during the quarter[40]. - The company reported a total of ¥140,006,372.45 in non-recurring gains and losses after tax adjustments[40].
泰格医药(03347) - 2022 Q1 - 季度财报